Molecular monitoring is indispensable for the clinical management of chronic myeloid leukemia (CML) patients. Real-time quantitative polymerase chain reaction (RT-qPCR) is the gold standard for the quantitative assessment of BCR-ABL transcript levels, which are critical in clinical decision-making. However, the frequent recurrence of the disease after drug discontinuation for 60% of patients has necessitated more sensitive and specific techniques to detect residual BCR-ABL transcripts. Here, we describe a quantification method for the detection of BCR-ABL targets at very low concentrations (<10 copies/sample) in the presence of a million copies of normal BCR and ABL genes. In this method, a fully modified locked nucleic acid (LNA) and a LNA...
Abstract Chronic myelogenous leukemia (CML) is the outcome of a chromosomal translocation and abl ...
Introduction. Ph+ ALL is observed in about 30% of adult ALL and is associated with a very poor progn...
The BCR-ABL1 positive ALL is the most frequent and prognostically most unfavorable subtype of ALL in...
For monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) the most recommended...
The BCR-ABL1 sequence has advantages over the BCR-ABL1 transcript as a molecular marker in chronic m...
We have developed a rapid real-time quantitative PCR method for measuring BCR-ABL mRNA levels in per...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Monitoring of minimal residual disease (MRD) by quantification of BCR-ABL1 transcript levels has bec...
Background: Detection of residual leukemic cells by measuring BCR-ABL1 transcript level with assays ...
Background: Detection of BCR-ABL1 transcript level via real-time quantitative-polymerase-chain react...
The reciprocal Philadelphia translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] creates a ...
Imatinib mesylate (IM) is the first line therapy against Chronic Myeloid Leukemia, effectively prolo...
Translocation t(9;22), which produces the BCR-ABL gene, is pathognomonic of chronic myeloid leukemia...
Abstract Chronic myelogenous leukemia (CML) is the outcome of a chromosomal translocation and abl ...
Introduction. Ph+ ALL is observed in about 30% of adult ALL and is associated with a very poor progn...
The BCR-ABL1 positive ALL is the most frequent and prognostically most unfavorable subtype of ALL in...
For monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) the most recommended...
The BCR-ABL1 sequence has advantages over the BCR-ABL1 transcript as a molecular marker in chronic m...
We have developed a rapid real-time quantitative PCR method for measuring BCR-ABL mRNA levels in per...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Monitoring of minimal residual disease (MRD) by quantification of BCR-ABL1 transcript levels has bec...
Background: Detection of residual leukemic cells by measuring BCR-ABL1 transcript level with assays ...
Background: Detection of BCR-ABL1 transcript level via real-time quantitative-polymerase-chain react...
The reciprocal Philadelphia translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] creates a ...
Imatinib mesylate (IM) is the first line therapy against Chronic Myeloid Leukemia, effectively prolo...
Translocation t(9;22), which produces the BCR-ABL gene, is pathognomonic of chronic myeloid leukemia...
Abstract Chronic myelogenous leukemia (CML) is the outcome of a chromosomal translocation and abl ...
Introduction. Ph+ ALL is observed in about 30% of adult ALL and is associated with a very poor progn...
The BCR-ABL1 positive ALL is the most frequent and prognostically most unfavorable subtype of ALL in...